Session Track · IDC 2027

Erythema at IDC 2027

Part of the IDC 2027 scientific program · NH Villa Carpegna, Rome, Italy · June 21–23, 2027

About the Erythema Session

Erythema is a medical condition caused by increased blood flow to a localized area of the skin or mucous membrane. It is often associated with inflammation and can range from a pink discoloration to a deep red hue. Typically, the color intensifies with increased blood flow and is relieved with decreased blood flow. Erythema is a very common condition and can be caused by many factors, including exposure to ultraviolet (UV) radiation, irritants, hot or cold temperatures, and certain medications or skin-care products. People with certain diseases, such as diabetes or lupus, may also be more prone to erythema. The primary symptom of erythema is redness of the affected area of skin or mucous membrane. Other associated symptoms can vary, depending on the cause. For example, erythema caused by UV radiation may be accompanied by skin itching and burning. If caused by irritants or certain medications, it may be accompanied by a rash, hives, sneezing, and swelling. Diagnosis is mainly based on the signs and symptoms associated with erythema. A physical exam may also be done to rule out other conditions. If the doctor suspects an underlying medical condition is the cause, they may order blood tests, imaging tests, or biopsies to determine the cause. Treatment may involve applying a topical cream, ointment, or gel, oral or topical medications to reduce inflammation, or phototherapy depending on the cause and severity of the erythema. It is important to talk to a doctor if any redness of the skin or mucous membrane persists or is accompanied by other symptoms. Prompt treatment can help reduce the severity of erythema and help prevent any further or lasting complications.

Featured Speakers — Erythema 2027

Speaker lineup for this track will be announced soon.

Browse all speakers →

Recent Research Presented at Erythema Sessions

Selected abstracts from this track will be published here.

Related Scientific Sessions at IDC 2027

Why Attend the Erythema Conference 2027

Present Your Research

Oral and poster slots for original Erythema work, reviewed by the scientific committee.

Network Globally

Meet researchers, clinicians, and industry leaders from around the world across three days.

Publish & Get Indexed

Accepted abstracts appear in the indexed conference proceedings with a citable DOI.

Learn from Keynotes

Plenary lectures from leading voices shaping Erythema research and practice.

Hybrid Flexibility

Attend in person in Rome or join virtually — same program, same certificate.

Join IDC 2027 for the Erythema track

Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.

Erythema Conference 2027 — FAQs

What is the Erythema track at IDC 2027?

The Erythema track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Erythema. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.

Who should attend the Erythema sessions?

Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Erythema are all welcome — whether presenting or attending.

Can I present my research in the Erythema track?

Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.

Is virtual attendance available for Erythema sessions?

Yes. IDC 2027 is a hybrid conference — attend the Erythema track in person in Rome or join live online, with on-demand access afterward.

Join the IDC 2027 delegation

Rome · June 21–23, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.